Clinical Trials Browser

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06151743 2024-04-30

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Phase 2 Recruiting

32 enrolled

Head & Neck

Locally Advanced Hypopharyngeal Carcinoma

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

264 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3 Recruiting

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06039631 2023-09-15

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Phase 2 Recruiting

82 enrolled

Head & Neck

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

Phase 3 Recruiting

228 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04807140 2023-04-14

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Phase 2 Recruiting

57 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05813626 2023-04-14

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Recruiting

89 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05628922 2022-11-29

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Phase 2 Recruiting

198 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT05340491 2022-08-31

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Phase 3 Recruiting

212 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04376866 2021-07-20

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

204 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

218 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT04453813 2020-09-28

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

226 enrolled

Head & Neck

Nasopharyngeal Carcinoma

Clinical Trials

(NeoScorch HN)

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

TRANSPARENT

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Study of CHS-114 in Participants With Advanced Solid Tumors

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Toripalimab With Chemotherapy for Sinus Cancer

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Navigation

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

GNT Induction Treatment in Locally Advanced NPC

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma